Healthcare -
Biotechnology - OTC - US
$ 0.0002
0.000003 %
$ 941
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart EFTR
FINANCIALS
Balance Sheet
eFFECTOR Therapeutics, Inc.
| Current Assets | 19.8 M |
| Cash & Short-Term Investments | 18.4 M |
| Receivables | 0 |
| Other Current Assets | 1.47 M |
| Non-Current Assets | 706 K |
| Long-Term Investments | 0 |
| PP&E | 193 K |
| Other Non-Current Assets | 513 K |
| Current Liabilities | 25.8 M |
| Accounts Payable | 2.33 M |
| Short-Term Debt | 20.5 M |
| Other Current Liabilities | 2.92 M |
| Non-Current Liabilities | 543 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 543 K |
EFFICIENCY
Earnings Waterfall
eFFECTOR Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 111 K |
| Gross Profit | -22.9 M |
| Operating Expenses | 33.8 M |
| Operating Income | -33.8 M |
| Other Expenses | 1.97 M |
| Net Income | -35.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
eFFECTOR Therapeutics, Inc.
| Net Income | -35.8 M |
| Depreciation & Amortization | 111 K |
| Capital Expenditures | -97 K |
| Stock-Based Compensation | 4.6 M |
| Change in Working Capital | 1.68 M |
| Others | 700 K |
| Free Cash Flow | -29.6 M |
Wall Street Analysts Price Targets
eFFECTOR Therapeutics, Inc.
EFTR has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
EFTR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
eFFECTOR Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 1 December, 2024. Stephen Van Deventer, CEO of BioGene, commented: "We are excited to welcome Dr. Brian Gallagher, Jr. to our Corporate Advisory Board.
newsfilecorp.com
- 4 months ago
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming bankruptcy risk stocks as they're grappling with the stark reality of financial distress.
investorplace.com
- 9 months ago
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a delisting of its securities and expects its securities to be delisted in the near term.
globenewswire.com
- 9 months ago
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.
globenewswire.com
- 11 months ago
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
eFFECTOR Therapeutics (NASDAQ: EFTR ) just reported results for the first quarter of 2024. eFFECTOR Therapeutics reported earnings per share of -$2.16.
investorplace.com
- 11 months ago
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif.
globenewswire.com
- 11 months ago
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
globenewswire.com
- 1 year ago
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
zacks.com
- 1 year ago
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. Based on 36 events, the hazard ratio for progression free survival (PFS, the primary endpoint of the study) using a stratified Cox proportional hazards model was 0.62 (95% confidence intervals 0.3 to 1.3) in favor of tomivosertib. The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively. Overall survival results remain immature, however no trend favoring tomivosertib was observed. There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.
globenewswire.com
- 1 year ago
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
globenewswire.com
- 1 year ago
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
globenewswire.com
- 1 year ago
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 1 year ago
8. Profile
Summary
eFFECTOR Therapeutics, Inc. EFTR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 941
Dividend Yield
0.00%
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Contact
142 North Cedros Avenue, Solana Beach, CA, 92075
https://effector.com
IPO
Date
March 1, 2021
Employees
14
Officers
Mr. Craig R. Jalbert CIRA
Chief Executive Officer, President, Treasurer &Secretary, and Director
Dr. Davide Ruggero Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board